Q-omics provides the consensus-scored YWHAQ profile across patient tissues and cancer cell-line models. YWHAQ expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, YWHAQ is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, YWHAQ protein abundance shows 23,126 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight MESO, HNSC, and PDAC as cancer lineages where YWHAQ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YWHAQ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YWHAQ survival associations across molecular data types. YWHAQ RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YWHAQ RNA expression–survival associations across cancer types. High YWHAQ expression shows unfavorable associations in MESO, ACC, LIHC, BLCA, HNSC and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for YWHAQ RNA expression.
This table summarizes YWHAQ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for YWHAQ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YWHAQ shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and BLCA. The HNSC box plot shows higher YWHAQ RNA expression in tumor versus normal tissue (log2 FC = +1.184, t-test p < 0.001).
This table shows molecular features associated with YWHAQ in patient tissues and cancer cell lines. In patient samples, YWHAQ shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, YWHAQ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
